Hereditary angioedema: first report of the Brazilian registry and challenges
Carregando...
Citações na Scopus
26
Tipo de produção
article
Data de publicação
2013
Editora
WILEY-BLACKWELL
Indexadores
Título da Revista
ISSN da Revista
Título do Volume
Autores
VALLE, S. O. R.
TOLEDO, E.
VILLELA, M. M. S.
MANSOUR, E.
PINTO, J. A.
CAMPOS, R. A.
FRANCA, A. T.
Autor de Grupo de pesquisa
Grp Interested HAE GINHA
Editores
Coordenadores
Organizadores
Citação
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, v.27, n.3, p.e338-e344, 2013
Resumo
Background Hereditary Angio-oedema (HAE) is a serious medical condition caused by a rare autosomal dominant genetic disorder, in which C1 inhibitor (C1-INH) function is reduced. There is no organized information on the HAE patient population in Brazil. Objective The Brazilian Registry was established to disseminate diagnostic access, and to better understand the main features of the disease in our country and its clinical impact. Methods A questionnaire was prepared and sent to specialists. The completed questionnaires were forwarded to the coordinating site and then entered into the Registry. Samples from patients with an unconfirmed diagnosis were tested for C1 inhibitor and C4 levels. Results From 2006 to 2010, 210 patients (133 females; mean age, 30 +/- 17years) were included. The median age of onset of symptoms and age at diagnosis were 6.5 and 21years, respectively; 80.9% of the patients had subcutaneous oedema, 54% gastrointestinal and 35.7% respiratory symptoms (21% had laryngeal oedema). Laparotomy due to the disease was performed in 6.2% of the patients. The majority of patients had Type I HAE of moderate severity. Twenty-seven per cent did not receive treatment; 53% were treated with danazol alone. Conclusion A paucity of patients with Type II HAE and a high frequency of laparotomy were observed, highlighting the need for better diagnosis in Brazil. HAE related educational activities, improved diagnosis and access to available therapy are needed in Brazil.
Palavras-chave
Referências
- AGOSTONI A, 1992, MEDICINE, V71, P206
- Banerji A, 2009, ALLERGY ASTHMA PROC, V30, P11, DOI 10.2500/aap.2009.30.3188
- Bork K, 2006, AM J MED, V119, P267, DOI 10.1016/j.amjmed.2005.09.064
- Bork K, 2001, ARCH INTERN MED, V161, P714, DOI 10.1001/archinte.161.5.714
- Bowen Tom, 2011, Allergy Asthma Clin Immunol, V7, P1, DOI 10.1186/1710-1492-7-1
- Cicardi M, 2010, NEW ENGL J MED, V363, P532, DOI 10.1056/NEJMoa0906393
- Cicardi M, 2012, ALLERGY, V67, P147, DOI 10.1111/j.1398-9995.2011.02751.x
- Cicardi M, 1997, J ALLERGY CLIN IMMUN, V99, P194, DOI 10.1016/S0091-6749(97)70095-2
- Craig T, 2009, ANN ALLERG ASTHMA IM, V102, P366, DOI 10.1016/S1081-1206(10)60506-6
- Davis III AE, 2008, CLIN MOL ALLERGY, V14, P2
- Eidelman Frank J, 2010, BMC Blood Disord, V10, P3, DOI 10.1186/1471-2326-10-3
- Fabiani J E, 2000, Allergol Immunopathol (Madr), V28, P267
- Farkas Henriette, 2010, Allergy Asthma Clin Immunol, V6, P18, DOI 10.1186/1710-1492-6-18
- Gompels MM, 2005, CLIN EXP IMMUNOL, V139, P379, DOI 10.1111/j.1365-2249.2005.02726.x
- Huang YT, 2005, ASIAN PAC J ALLERGY, V23, P227
- Longhurst Hilary J, 2010, Vasc Health Risk Manag, V6, P795
- Lunn ML, 2010, ANN ALLERG ASTHMA IM, V104, P211, DOI 10.1016/j.anai.2009.12.004
- Mallbris Lotus, 2007, BMC Dermatol, V7, P6, DOI 10.1186/1471-5945-7-6
- Maurer M, 2011, J DTSCH DERMATOL GES, V9, P99, DOI 10.1111/j.1610-0387.2010.07546.x
- Nzeako UC, 2001, ARCH INTERN MED, V161, P2417, DOI 10.1001/archinte.161.20.2417
- Nzeako UC, 2010, WORLD J GASTROENTERO, V16, P4913, DOI 10.3748/wjg.v16.i39.4913
- Reshef A, 2008, ISR MED ASSOC J, V10, P850
- Roche O, 2005, ANN ALLERG ASTHMA IM, V94, P498
- Romero DSF, 2009, MEDICINA-BUENOS AIRE, V69, P601
- Varga L, 2007, MOL IMMUNOL, V44, P1454, DOI 10.1016/j.molimm.2006.04.020
- Zuraw Bruce L, 2010, Allergy Asthma Clin Immunol, V6, P23, DOI 10.1186/1710-1492-6-23